Cartesian Therapeutics (RNAC) Treasury Shares (2015 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Treasury Shares data on file, last reported at $736272.0 in Q1 2026.

• On a quarterly basis, Treasury Shares rose 28.58% year-over-year to $736272.0 in Q1 2026; TTM through Mar 2026 was $736272.0, a 28.58% increase from a year earlier, with the FY2025 full-year figure at $522498.0, up 17.62% from the prior year.
• Treasury Shares for Q1 2026 stood at $736272.0, up from $522498.0 in the prior quarter.
• Over the last five years, Treasury Shares for RNAC reached as high as $2.5 million in Q1 2023 and fell as low as $435120.5 in Q4 2023.
• Historically, Treasury Shares has averaged $1.1 million across 5 years, with a median of $736272.0 in 2026.
• Across the five-year window, Treasury Shares surged 215.17% in 2022 and rose 2.1% in 2024, its largest moves.
• Year by year, Treasury Shares stood at $1.8 million in 2022, then plunged by 75.43% to $435120.5 in 2023, then rose by 2.1% to $444238.0 in 2024, then gained by 17.62% to $522498.0 in 2025, then jumped by 40.91% to $736272.0 in 2026.
• Per Business Quant data, the three most recent Treasury Shares figures were $736272.0 in Q1 2026, $522498.0 in Q4 2025, and $523254.0 in Q3 2025.